a Cohort Study (Gut Microbiota and HCC)

Primary Outcomes (8)

• Objective Progression-Free Survival (PFS)

  To analyse the Progression-Free Survival (PFS) of patients

  Up to approximately 1 years

• Objective Secondary Clinical Endpoints - Overall Growth Phase (OS)

  To analyse the Secondary Clinical Endpoints - Overall Growth Phase (OS) of patients

  Up to approximately 1 years

• Objective Objective Response Rate (ORR)

  To exprole the Objective Response Rate (ORR) of patients

  Up to approximately 1 years

• ObjectiveDuration of Response (DOR)

  To analyse the Duration of Response (DOR) of patients

  Up to approximately 1 years

• Diversity analysis

  We will use 16S rRNA sequencing to measure fecal sample. The alpha and beta diversity of gut microbiota will be analyzed, including a series of statistical analysis indexes such as Chao, Shannon, Simpsonace, Simpson and Coverage, in order to reflect the microbial community diversity.

  0 weeks, 12 weeks, 24 weeks and 48 weeks

• Species differential analysis

  We will use 16S rRNA sequencing to measure fecal sample. Based on the results of species annotation, the PCA、PCoA and NMDS analysis will be used to assess the similarities and differences in species composition.

  0 weeks, 12 weeks, 24 weeks and 48 weeks

• Feces Metabolomics

  Changes of metabolites in feces measured by metabolomic mass spectrometry, unsupervised PCA (principal component analysis) was performed by statistics function prcomp, identified metabolites were annotated using KEGG Compound database.

  0 weeks, 12 weeks, 24 weeks and 48 weeks

• Serum Metabolomics

  Changes of metabolites in serum measured by metabolomic mass spectrometry, unsupervised PCA (principal component analysis) was performed by statistics function prcomp, identified metabolites were annotated using KEGG Compound database.

  0 weeks, 12 weeks, 24 weeks and 48 weeks

Conditions